Jochen Greiner
Overview
Explore the profile of Jochen Greiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoffmann S, Schrezenmeier E, Desmarets M, Halleck F, Durrbach A, Peters L, et al.
EBioMedicine
. 2025 Feb;
113:105613.
PMID: 40020259
Background: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP in immunocompromised individuals with mild COVID-19. Methods:...
2.
Orlowski-Scherer J, Maccarone T, Bright J, Kaminski T, Koss M, Mohan A, et al.
Open Res Eur
. 2025 Jan;
4:132.
PMID: 39850745
The study of transient and variable events, including novae, active galactic nuclei, and black hole binaries, has historically been a fruitful path for elucidating the evolutionary mechanisms of our universe....
3.
Greiner J, Mohamed E, Fletcher D, Schuler P, Schrezenmeier H, Gotz M, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456538
Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid progenitor cells. Nucleophosmin 1 (NPM1) gene...
4.
Fischer L, Jiang L, Durig J, Schmidt C, Stilgenbauer S, Bouabdallah K, et al.
Leukemia
. 2024 Apr;
38(6):1307-1314.
PMID: 38678093
The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy...
5.
Guinn B, Schuler P, Schrezenmeier H, Hofmann S, Weiss J, Bulach C, et al.
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298237
Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell...
6.
Greiner J, Goetz M, Schuler P, Bulach C, Hofmann S, Schrezenmeier H, et al.
Br J Haematol
. 2022 Jul;
198(5):866-874.
PMID: 35799423
Nucleophosmin1 (NPM1) is one of the most commonly mutated genes in AML and is often associated with a favourable prognosis. Immune responses play an increasing role in AML treatment decisions;...
7.
Kuster O, Schmohl J, Greiner J, Storz M
Eur J Med Res
. 2022 May;
27(1):63.
PMID: 35505368
Background: Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by low platelet counts and increased bleeding risk. The disease may be induced by other disorders, including malignancies, autoimmune diseases,...
8.
Greiner J, Gotz M, Wais V
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328721
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The standard of care in medically and physically fit patients is intensive induction therapy. The majority of these...
9.
Greiner J, Brown E, Bullinger L, Hills R, Morris V, Dohner H, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638823
Despite recent advances in therapies including immunotherapy, patients with acute myeloid leukaemia (AML) still experience relatively poor survival rates. The Inhibition of Apoptosis (IAP) family member, survivin, also known by...
10.
Jung S, Greiner J, von Harsdorf S, Popovic P, Moll R, Schittenhelm J, et al.
Blood Adv
. 2021 Sep;
5(19):3789-3793.
PMID: 34496024
Treatment with CD19-directed (CAR) T cells has evolved as a standard of care for multiply relapsed or refractory large B-cell lymphoma (r/r LBCL). A common side effect of this treatment...